Clinical efficacy of pneumococcal vaccine in the elderly: A randomized, single-blind population-based trial

American Journal of Medicine

Volumn 103, Issue 4, 1997, Pages 281-290

  Koivula, Irma ^a   Stén, Marja ^b   Leinonen, Maija ^c   Mäkelä, Pirjo Helena ^c  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b Varkaus Health Centre   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUPAR VACCIN; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLOOD CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FINLAND; HIGH RISK POPULATION; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SINGLE BLIND PROCEDURE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; VACCINATION;

AGED; BACTERIAL VACCINES; CATCHMENT AREA (HEALTH); FEMALE; FINLAND; HUMANS; INCIDENCE; INFLUENZA VACCINES; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; SINGLE-BLIND METHOD; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 0343329899     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00149-6     Document Type: Article

References (49)

1. La Croix AZ, Lipson S, Miles T, White L. Prospective study of pneumonia hospitalizations and mortality of U.S. older people: the role of chronic conditions, health behaviors and nutritional status. Public Health Rep. 1989;104: 350-369.
2. Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in Eastern Finland. Am J Epidemiol. 1993;137:977-988.
3. Berntsson E, Lagergård T, Strannegård Ö, Trollfors B. Etiology of community-acquired pneumonia in outpatients. Eur J Clin Microbiol Infect Dis. 1986;5:446-447.
4. Woodhead MA, Mcfarlane JT, McCracken, et al. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet. 1987;1:671-674.
5. Fedson D, Henrichsen J, Mäkelä PH. Immunization of elderly people with pneumococcal vaccine. Infection. 1989;17:437-441.
6. Bentley DW. Pneumococcal vaccine in the institutionalized elderly: review of past and recent studies. Rev Inf Dis. 1981;3(suppl):61-70.
7. Austrian R, Douglas RM, Schiffman G, et al. Prevention of pneumococcal infection by vaccination. Trans Am Physicians. 1976;89:184-194.
8. Smit P, Oberholzer D, Hayden-Smith S, et al. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA. 1977;238:2613-2616.
9. Riley ID, Tarr PI, Andrews M, et al. Immunization with a polyvalent pneumococcal vaccine. Reduction of adult respiratory mortality in a New Guinea Highlands community. Lancet. 1977;i:1338-1341.
10. Shapiro ED, Clemens JD. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med. 1984;101:325-330.
11. Bolan G, Broome CV, Facklam RR, et al. Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med. 1986;104:1-6.
12. Sims RV, Steinman WC, McConville JH, et al. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med. 1988;108:653-657.
13. Farr BM, Johnston BL, Cobb DK, et al. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch Intern Med. 1995;155:2336-2340.
14. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. NEJM. 1991;325:1453-1460.
15. Austrian R. Surveillance of pneumococcal infection for field trials of polyvalent pneumococcal vaccines. Bethesda, MD: National Institute of Health 1980. Publication DAB-VDP-12-84.
16. Simberkoff MS, Cross AP, Al-Ibrahim M, et al. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. NEJM. 1986;315:1318-1327.
17. Leech JA, Gervais A, Ruben FL. Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Can Med Assoc J. 1987;136:361-365.
18. Hirschmann JV, Lipsky BA. The pneumococcal vaccine after 15 years of use. Arch Intern Med. 1994;154:373-377.
19. Gaillat J, Zmirou D, Mallaret MR, et al. Essai clinique du vaccin antipneumococcique chez des personnes âgées vivant en institution. Rev Epidemiol Sante Publique. 1985;33:437-444.
20. Spika JS, Fedson DS, Facklam RR. Pneumococcal vaccination. Controversies and opportunities, Inf Dis Clin North Am. 1990;4:11-27.
21. Simberkoff MS. Pneumococcal vaccine in prevention of community-acquired pneumonia: a skeptical view of cost-effectiveness. Semin Resp Inf. 1993;8:294-299.
22. Fedson D. Pneumococcal vaccination in the prevention of community-acquired pneumonia. An optimistic view of cost-effectiveness. Semin Resp Inf. 1993;8:285-293.
23. Jalonen E, Taira S, Paton JC, Kerttula Y, et al. Pneumolysin produced in Bacillus subtilis as antigen for measurement of pneumococcal antibodies by enzyme immunoassay. Serodiagn lmmunother Infect Dis. 1990;4:451-458.
24. Leinonen M, Syrjälä H, Jalonen E, et al. Demonstration of pneumolysin antibodies in dissociated immune complexes - a new method for etiological diagnosis of pneumococcal pneumonia. Serodiagn Immunother Infect Dis. 1990;4:459-468.
25. Centers for Disease Control. Pneumococcal and influenza vaccination levels among adults aged ≥65 years - United States, 1993. MMWR. 1996;45: 853-859.
26. Ruben FL, Uhrin M. Specific immunoglobulin-class antibody responses in the elderly before and after 14-valent pneumococcal vaccine. J Infect Dis. 1985;151:845-849.
27. Sankilampi U, Honkanen PO, Bloigu A, et al. Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly. J Inf Dis. 1996;173: 387-393.
28. Koivula I, Sten M, Mäkelä PH. Risk factors for pneumonia in the elderly. Am J Med. 1994;96:313-320.
29. Honkanen P, Keistinen T, Kivelä S-L. The impact of vaccination strategy and methods of information on influenza and pneumococcal vaccination coverage in the elderly population. Vaccine. 1997;15:317-320.
30. World Health Organization: Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death. Eight Revision. Geneva, 1966.
31. World Health Organization: Instructions for Physicians on Use of International Form of Medical Certificate of Cause of Death. Geneva, 1968.
32. Mcfarlane JT, Finch RG, Ward MJ, Mcrae AD. Hospital study of adult community-acquired pneumonia. Lancet. 1982;2:255-258.
33. Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis. 1989;11:586-599.
34. Meyer RD, Finch RG. Community acquired pneumonia. J Hosp Inf. 1992;22:51-59.
35. Valenti WM, Jenzer M, Bentley DW. Type-specific pneumococcal respiratory disease in the elderly and chronically ill. Am Rev Respir Dis. 1978;117:233-238.
36. SPSSX User's guide, 2nd edn., New York:McGraw-Hill Book Company, 1986.
37. Kleinbaum DG, Kupper LL, Morgenstern H, eds. Epidemiologic Research. Principles and Quantitative methods. New York: Van Nostrand Reinhold, 1982;296-299.
38. Kaufman P. Pneumonia in old age. Arch Intern Med. 1947;79:518-531.
39. Sankilampi LJ, Herva E, Haikala R, et al. Epidemiology of invasive infections in adults in Finland. Epidemiol Infect. 1997;118:7-15.
40. Rein MF, Gwaltney JM, O'Brien WM, et al. Accuracy of the gram's stain in identifying pneumococci in sputum. JAMA. 1978;239:2671-2673.
41. Kalin M, Kanclerski K, Granström M, Möllby R. Diagnosis of pneumococcal pneumonia by enzyme-linked immunosorbent assay of antibodies to pneumococcal hemolysin (pneumolysin). J Clin Microbiol. 1987;25:226-229.
42. Jalonen E, Paton JC, Koskela M, et al. Measurement of antibody responses to pneumolysin - a promising method for the presumptive aetiological diagnosis of pneumococcal pneumonia. J Infect. 1989;19:127-134.
43. Kanclerski K, Blomqvist S, Granström M, Möllby R. Serum antibodies to pneumolysin in patients with pneumonia. J Clin Microbiol. 1988;26:96-100.
44. Örtquist A, Hedlund J, Grillner L, et al. Aetiology, outcome and prognostig factors in community acquired pneumonia requiring hospitalization. Eur Resp J. 1990;3:1105-1113.
45. Kauppinen MT, Herva E, Kujala P, et al. The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland. J Infect Dis. 1995:172:1330-1335.
46. Lieberman D, Schlaeffer F, Bldur I, et al. Multiple pathogen in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax. 1996:51:179-184.
47. Berntsson E, Blomberg J, Lagergard T, et al. Etiology of community-acquired pneumonia in out-patients. Eur J Clin Microbiol. 1986:5:446-447.
48. Patrick KM, Woolley FR. A cost-benefit analysis of immunization for pneumococcal pneumonia. JAMA. 1981:245:473-477.
49. Perez-Tirse J, Gross PA. Review of cost-benefit analyses of influenza vaccine. PharmacoEconomics 1992;2(3):198-206.